Intended for US audiences only.

Recycling Infusion Materials Guide

What You Will Receive

If you are an eligible patient who is currently taking or about to begin treatment with cutaquig® and opted in for the complimentary IgCares recycling program, you'll receive everything you need to properly dispose of all your infusion materials. You will receive:


Sharps Recovery System

Infusion Supply Recovery System

Instructions and Info

Detailed instructions about what materials to recycle in the sharps container, how to do so properly, and how to ship it back.

Instructions and Info

Detailed instructions about what materials to recycle in the cooler ship-back box, how to do so properly, and how to ship it back.

Sharps Containers

Two 1-gallon sharps containers. Once we receive a returned container at the recycling center, we'll mail you a new replacement. Mailing two containers initially ensures you'll never be left without one!

Prepaid Return Box

One return box with a prepaid UPS shipping label so you can mail your filled box back to the recycling facility free of charge. You'll be mailed an additional return box automatically.

Prepaid Return Box

One return box with a prepaid USPS shipping label so you can mail your filled container back to the recycling facility free of charge. You'll be mailed an additional return box each time you receive a replacement Sharps container.

Additional Materials

All of the additional materials required for shipping, including plastic bags, twist ties and tape.

What goes in
Vented spike adapters
Syringe needles
Needle sets
Empty product vials
Biohazardous materials

Additional Materials

All of the additional materials required for shipping, including plastic bags, twist ties and tape.

What goes in
Everything shipped with your prescription that doesn't go in your Sharps container, including:
Foam cooler
Ice packs
Sterile drapes with packaging
Plastic syringe with packaging
Rate flow tubing and packaging
Alcohol wipes and packaging
Transparent dressing and packaging
Gauze and packaging
Topical cream tube
Do not include anything sharp or breakable

Step by Step Recycling Instructions

Infusion Supply Recycling
Sharps Recycling
Infusion Supply Recycling
Infusion Supply Recycling

1

Remove container from packaging and place at point of use. Do not remove absorbent pad from container.

2

Save the return shipping box that already has the pre-paid return label attached, as well as the associated components (plastic bag, twist tie, and tape). This is the box you'll use to return your container.

3

After each infusion, place sharps and other biohazardous materials into the container. Do not overfill. (Hint: biohazardous material is anything that came into contact with your bodily fluids)

4

Close lid by snapping firmly over opening. Make sure lid is tightly sealed prior to packaging.

5

When ready to return a container, place it into the plastic bag and then into the return shipping box. Only mail container in original return box.

6

Securely seal the bag around the container using the included twist-tie.

7

Close the numbered shipping box flaps in order. The Return Label must be showing.

8

Place the included tape over closer flap as pictured above.

9

Remove Tracking Form from plastic pouch on shipping box. Complete top section. You must sign the form. Remove bottom copy and keep. Place remaining copies back in pouch with barcode facing out. Box will not be accepted without tracking form.

10

Fill out your return to sender address in the area provided on top of the return box and then give it to your USPS mail carrier, drop it off at a USPS office or request a USPS pickup. No additional postage is necessary. Total package may not weigh more than the weight listed on the shipping box.

That's it! Once your box is processed at the recycling center, patients who are IgCares Support Program members will earn 1 donation point.

We'll also automatically send you a new Sharps container and the associated return box with pre-paid USPS shipping label.

In case of damage to the Sharps container or for general assistance, please call 800-772-5657.


1

Refer to the Infusion Supply Recovery System™ list above to ensure that each item is being placed in the proper container.

2

Save this shipping box and all the components it contains for returning your infusion supplies at the end of each month.

3

Save the foam cooler from your infusion supplies and use the cooler to dispose of all the materials listed above at the end of each month.

4

At the end of the month, put the top on the foam cooler and place it in the included 4-mil large plastic bag, then securely seal using the included tie wrap.

5

Place the bagged foam cooler, itemized list of contents (and any other appropriate materials) into the second 4-mil large plastic bag, securely sealing everything with the second tie wrap. Place the double-bagged cooler into the prepaid, prelabeled UPS Ground–only shipping box.

6

Close the shipping box flaps, leaving “Return Shipping Panel” exposed. The ship-to label must be showing.

7

Tape the shipping box closed with the included packaging tape, making sure that the UPS prepaid return shipping label is visible.

8

Hand the shipping box to a UPS driver, or schedule a UPS pickup by calling Customer Support at 800-772-5657. All shipping charges are prepaid; no additional costs are required.

That's it! Once your box is processed at the recycling center, patients who are IgCares Support Program members will earn 1 donation point.

We'll also automatically send you a new Infusion Supply Recovery System and the associated return box with pre-paid UPS shipping label.

In case of damage to the Infusion Supply Recovery System or for general assistance, please call 800-772-5657.




Program Recycling Impact

ENERGY GENERATED (kWh)
of renewable energy
lbs
TOTAL WEIGHT
DIVERTED FROM LANDFILLS
ELECTRICITY
TO POWER
HOMES FOR A MONTH
REDUCTION OF
LBS OF CO2 EQUIVALENT
GREENHOUSE GASES
Indications and Important Safety Information for cutaquig® (Immune Globulin Subcutaneous [Human]– hipp, 16.5% solution)
WARNING: THROMBOSIS
See the cutaquig full prescribing information for complete boxed warning
Thrombosis may occur with immune globulin products, including cutaquig.

Indications and Important Safety Information for cutaquig® (Immune Globulin Subcutaneous [Human]– hipp, 16.5% solution)

WARNING: THROMBOSIS

See the cutaquig full prescribing information for complete boxed warning

Thrombosis may occur with immune globulin products, including cutaquig.

Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.

For patients at risk of thrombosis, administer cutaquig at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

Indications and Usage

Cutaquig® (Immune Globulin Subcutaneous (Human)-hipp) is a 16.5% immune globulin solution for subcutaneous infusion (IGSC), indicated as replacement therapy for primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

IMPORTANT SAFETY INFORMATION

Contraindications

Cutaquig is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the subcutaneous administration of human immune globulin or to any of the components of cutaquig such as Polysorbate 80, and in IgA-deficient patients with antibodies against IgA and a history of hypersensitivity.

Warnings and Precautions

Severe hypersensitivity reactions may occur with cutaquig, even in patients who tolerated previous treatment with human immune globulin. If a hypersensitivity reaction occurs, discontinue the cutaquig infusion immediately and initiate appropriate treatment. IgA-deficient patients with anti-IgA antibodies are at greater risk of severe reactions.

Thrombosis may occur following treatment with immune globulin products, including cutaquig. For patients at risk of thrombosis, administer cutaquig at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

Falsely elevated blood glucose readings may occur during and after the infusion of cutaquig with some glucometer and test strip systems. When administering cutaquig, measure blood glucose with a glucose-specific method.

Aseptic meningitis syndrome (AMS) can occur with cutaquig. AMS has been reported after the use of human immune globulin administered intravenously and subcutaneously and may occur within 2 days following treatment. Discontinuation of immunoglobulin treatment has resulted in remission within several days without sequelae.

Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis and death may occur with use of human immune globulin, especially those containing sucrose. cutaquig does not contain sucrose. Monitor patients for signs and symptoms of renal dysfunction. Monitor blood urea nitrogen, serum creatinine, and urine output in patients at risk of acute renal failure.

Monitor cutaquig recipients for clinical signs and symptoms of hemolysis, particularly patients with pre-existing anemia and/or cardiovascular or pulmonary compromise. Consider appropriate confirmatory laboratory testing if signs and symptoms of hemolysis are present after cutaquig infusion.

Non-cardiogenic pulmonary edema may occur in patients administered human immune globulin products. Monitor for pulmonary adverse reactions (transfusion-related acute lung injury, TRALI). If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies in both the product and patient’s serum. Patients with TRALI may be managed using oxygen therapy with adequate ventilatory support.

Cutaquig is made from human plasma and may carry a risk of transmitting infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Drug Interactions

After infusion of cutaquig, the transitory rise of the various passively transferred antibodies in the patient’s blood may yield false positive serological test results, with the potential for misleading interpretation.

Adverse Reactions

The most common adverse reactions (≥ 5% of study subjects) were local infusion site reactions (such as redness, swelling, itching), headache, fever, dermatitis, asthma, diarrhea, and cough.

Please see the cutaquig full prescribing information

CUTA-0624
Octapharma
Home | Product Site | Healthcare Professionals Site | Terms of Use | Data Privacy Statement | California Required Statements
© 2025 Octapharma USA Inc. All rights reserved | About Octapharma |

This website uses cookies and stores information on your computer. Some of them are essential to improve our website and your user experience. By using this website, you agree to the use of these cookies. Please check our Data Privacy Statement for more details.